Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Dodge & Cox Stock Fund 2026 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (Dodge & Cox Stock Fund)

Primary Source Intelligence • Q3 2026 Letter Analysis

Dodge & Cox Stock Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Dodge & Cox Stock Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+1.3%

YTD+5.16%

Annualized+8.88%

Positioning StanceCONSTRUCTIVE

GeographyUS

Digest Analysis

Quick Take

"Driven by relative gains from an underweight in Consumer Discretionary and holdings in Avantor, while establishing new positions in Boston Scientific and Danaher amid market dislocations."

Executive Summary

Dodge & Cox Stock Fund (Class I) returned 1.30% net of fees in the third quarter of 2026, trailing the S&P 500 Index's 2.30% gain and the Russell 1000 Value Index's 2.61% advance. Year to date, the Fund has returned 5.16% net of fees, lagging the S&P 500 and Russell 1000 Value by 7.6 and 14.1 percentage points, respectively. Relative performance during the quarter was dampened by an underweight posture in Information Technology alongside stock selection in Health Care, though underweight allocations to Consumer Discretionary and Utilities partially mitigated benchmark underperformance. The macroeconomic landscape was shaped by persistent inflation, durable U.S. economic growth, and substantial debt financing for artificial intelligence infrastructure, which prompted the Federal Reserve to raise short-term rates by 25 basis points. Long-term interest rates expanded concurrently, driving 10-year Treasury yields to their highest levels since 2007. Market concentration remained historically elevated, with the five largest constituents representing 31% of S&P 500 capitalization, despite a sharp quarterly pullback across semiconductor shares driven by questions over artificial intelligence spending durability. Capitalizing on artificial intelligence sentiment dislocations, management initiated new positions in franchises where disruption risks appear overstated, such as Roper Technologies, while scaling exposure to long-term beneficiaries including Microsoft and Amazon. Within Health Care, the Fund rotated capital away from pharmaceuticals into Life Sciences Tools and Medical Equipment, establishing new holdings in Boston Scientific and Danaher following multi-year destocking cycles. The aggregate portfolio trades at 13.4 times forward earnings, reflecting a substantial discount to the S&P 500.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

65%

CautiousHigh

Moderate (65%)

Positioning reflects a disciplined value approach with individual top-ten positions weighted between 2.2% and 4.2%. While portfolio actions display conviction in specific contrarian additions like Roper, Danaher, and Boston Scientific, overall concentration is constrained by mutual fund diversification parameters.

Growth Outlook

55%

BearishBullish

Neutral (55%)

The manager expresses caution over narrow market breadth, elevated broader equity multiples, and climbing bond yields, yet remains constructive on the portfolio's substantial valuation discount of 13.4 times forward earnings versus the S&P 500's 19.2 times.

Risk Appetite

60%

DefensiveAggressive

Balanced (60%)

The fund maintains an equity-focused stance, actively buying cyclical inflection stories like Danaher and initiating positions in dislocated software and medical device names while remaining underweight expensive mega-cap tech benchmarks.

Capital Deployment

70%

De-riskingDeploying

Deploying (70%)

Capital deployment was demonstrated through initiated positions in Boston Scientific, Danaher, and Roper Technologies, paired with additions to existing holdings Microsoft and Amazon.

Forward Guidance

65%

CautiousExpansionary

Expansionary (65%)

Management signals an active posture in redeploying capital toward dislocated franchises where short-term pressures create attractive entry multiples, notably across life sciences, medical equipment, and overlooked software compounders.

Language Signal

55%

BearishBullish

Balanced (55%)

The letter balances optimistic vocabulary regarding attractive valuations, long-term fundamentals, and recovery cycles against persistent warnings on extreme index concentration, inflation, and multi-decade highs in Treasury yields.

Perceived Risk

65%

Low RiskElevated

Elevated Risk (65%)

The team explicitly underscores systemic macro risks including the Federal Reserve's rate hike, 10-year Treasury yields reaching 2007 highs, sustained inflation, and dangerous index concentration in five mega-cap names.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

Management highlights an attractive opportunity set stemming from market overreactions to AI threats and multi-year inventory destocking cycles in health care equipment and tools.

Time Horizon

80%

Short-TermLong-Term

Decade+ (80%)

The manager explicitly emphasizes a three- to five-year investment horizon, advising shareholders to look through short-term benchmark volatility in favor of long-term business fundamentals.